These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 17223435

  • 1. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA, Kaul S.
    Am J Cardiol; 2007 Jan 15; 99(2):284-7. PubMed ID: 17223435
    [Abstract] [Full Text] [Related]

  • 2. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.
    Kaul S, Diamond GA.
    Prog Cardiovasc Dis; 2007 Jan 15; 49(4):284-99. PubMed ID: 17185116
    [Abstract] [Full Text] [Related]

  • 3. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials.
    Diamond GA, Kaul S.
    J Am Coll Cardiol; 2004 Jun 02; 43(11):1929-39. PubMed ID: 15172393
    [Abstract] [Full Text] [Related]

  • 4. Randomization as a basis for inference in noninferiority trials.
    Wiens BL.
    Pharm Stat; 2006 Jun 02; 5(4):265-71. PubMed ID: 17128425
    [Abstract] [Full Text] [Related]

  • 5. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.
    Kim MY, Xue X.
    J Clin Epidemiol; 2004 Dec 02; 57(12):1253-61. PubMed ID: 15617951
    [Abstract] [Full Text] [Related]

  • 6. A more powerful exact test of noninferiority from binary matched-pairs data.
    Lloyd CJ, Moldovan MV.
    Stat Med; 2008 Aug 15; 27(18):3540-9. PubMed ID: 18314932
    [Abstract] [Full Text] [Related]

  • 7. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA, Wu R, Tiwari RC.
    J Biopharm Stat; 2011 Sep 15; 21(5):902-19. PubMed ID: 21830922
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF, Kim CY, Li H.
    Stat Med; 2004 Apr 30; 23(8):1297-309. PubMed ID: 15083484
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fallacies in clinical cardiovascular trials.
    Swedberg K.
    Heart; 2009 Sep 30; 95(17):1464-8. PubMed ID: 19684197
    [No Abstract] [Full Text] [Related]

  • 16. Re: "use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection".
    van Noord PA, van der Tweel I.
    Am J Epidemiol; 2005 Nov 15; 162(10):1033-5. PubMed ID: 16221807
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.
    Kohro T, Yamazaki T.
    Hypertens Res; 2009 Feb 15; 32(2):109-14. PubMed ID: 19262468
    [Abstract] [Full Text] [Related]

  • 18. Trials and tribulations of noninferiority: the ximelagatran experience.
    Albers GW, Diener HC, Frison L, Grind M, Horrow J, Nevinson M, Olsson SB, Partridge S, Petersen P, Vahanian A, Halperin JL, Executive Steering Committee for the SPORTIF III and V Investigators.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):1058; author reply 1059. PubMed ID: 16949503
    [No Abstract] [Full Text] [Related]

  • 19. Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.
    Hida E, Tango T.
    J Biopharm Stat; 2013 Sep 05; 23(4):774-89. PubMed ID: 23799810
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.